Over the past decade, ketamine and esketamine (Spravato®) have become increasingly recognized for their potential to treat depression—especially for individuals who have not responded to traditional antidepressants. Yet for both patients and prescribers, these treatments remain challenging to access and sustain. High costs, constrained availability, and time-intensive treatment protocols continue to limit who can benefit from them.
Despite their growing clinical use, research consistently underscores that long-term data on ketamine’s safety, efficacy, and maintenance strategies remain insufficient. While studies point to promising antidepressant effects, they also emphasize the need for larger, high-quality trials to clarify best practices and long-term outcomes.
Encouragingly, existing data suggest that misuse or addiction in supervised medical settings appears rare. A 2022 review by J. Swainson and colleagues noted that “appropriate treatment of depression with ketamine when indicated may actually reduce misuse or abuse of substances, including ketamine used to self-medicate” (p. 244). This finding suggests that when ketamine is used judiciously and within a structured therapeutic framework, it may act as a protective factor rather than a risk factor for substance misuse.
Although the exact mechanisms of ketamine’s antidepressant effects are not fully understood, researchers have identified its role in modulating the glutamate system—a neurotransmitter pathway critical for neuroplasticity and mood regulation. By influencing this system, ketamine appears to “reset” patterns of brain activity linked to depression, often resulting in rapid symptom relief.
Emerging evidence also points to ketamine’s potential role in treating substance use disorders (SUDs). While these early findings are encouraging, experts caution that this area of research remains in its infancy. Questions regarding long-term outcomes, maintenance dosing, and sustained efficacy remain open and require further investigation.
As Swainson et al. (2022) advise, “any ongoing or maintenance use of ketamine for depression should be reserved for patients who have exhausted other treatment options, including multiple trials of antidepressants and other more evidence-based augmentation strategies” (p. 246). This underscores the importance of clinical discretion—ketamine should not be a first-line intervention but a carefully considered option for treatment-resistant cases.
For prescribers, vigilance and ethical oversight are key. Although ketamine’s therapeutic potential is significant, it carries inherent risks. Clinicians are encouraged to:
- Conduct thorough screening and risk assessments, especially for clients with a history of substance use.
- Monitor ongoing treatment closely, particularly in maintenance or off-label contexts.
- Avoid over-reliance on subjective reports of insight or relief, balancing them with objective measures of progress and functioning.
When used responsibly, ketamine can provide meaningful relief to individuals who have exhausted conventional treatments. Yet the growing enthusiasm for ketamine must be matched with structure, caution, and transparency.
The mental health field stands at a pivotal moment—ketamine represents both innovation and uncertainty. Moving forward, the research community continues to call for rigorous, long-term studies to better understand optimal dosing, duration, and the sustainability of therapeutic benefits.
Until then, clinicians and patients alike are encouraged to approach ketamine treatment with curiosity, informed caution, and collaboration—balancing hope with evidence, and innovation with ethical care.
Here is the 2022 article by J. Swainson and colleagues that goes into further depth of what is summarized above:
